0001193125-26-083012
SEC filingAldeyra Therapeutics, Inc. reported a net loss of $33.8 million for the fiscal year ended December 31, 2025, an improvement from a net loss of $55.9 million in the prior year. The company generated no revenue, with losses driven by research and development expenses of $25.7 million and general and administrative expenses of $9.6 million. The reduction in net loss was primarily due to decreased R&D spending, which fell by $22.6 million (46.8%) year-over-year, reflecting lower clinical development and drug manufacturing costs. The company ended the period with $70.0 million in cash and cash equivalents, total assets of $72.1 million, and stockholders' equity of $44.3 million. Key forward-looking events include the FDA's PDUFA date of March 16, 2026, for the reproxalap NDA and the potential exercise of the AbbVie Option for commercialization.
Aldeyra Therapeutics, Inc. reported a net loss of $33.8 million for the fiscal year ended December 31, 2025, compared to a net loss of $55.9 million in the prior year, representing a 39.4% improvement. The loss from operations was $35.3 million, a 41.3% improvement from the $60.1 million loss in 2024. The company generated no revenue during the period. The improvement in net loss was primarily driven by a significant reduction in research and development expenses, which decreased by $22.6 million (46.8%) to $25.7 million, and a decrease in general and administrative expenses of $2.3 million (19.3%) to $9.6 million. Other income, net, was $1.4 million, consisting of $3.3 million in interest income offset by $1.9 million in interest expense.
The company generated no revenue from product sales during the fiscal year 2025. Aldeyra's ability to generate future revenue depends on obtaining regulatory approval and successfully commercializing its lead product candidate, reproxalap, for the treatment of dry eye disease. The company submitted an NDA for reproxalap in December 2022, received Complete Response Letters in 2023 and 2025, and resubmitted the NDA in June 2025. The FDA accepted the resubmission and assigned a PDUFA date of December 16, 2025, which was later extended to March 16, 2026, after the FDA requested submission of additional field trial data. The company has an exclusive option agreement with AbbVie for potential commercialization.
As a pre-revenue biotechnology company, Aldeyra reported negative operating and net income margins. The operating loss margin improved due to reduced operating expenses. Research and development expenses decreased by 46.8% year-over-year, primarily due to lower external clinical development costs ($10.5 million decrease), reduced drug product manufacturing costs ($8.5 million decrease), and decreased personnel and consulting costs. General and administrative expenses decreased by 19.3%, mainly due to reductions in personnel and legal expenditures. The company's cost structure remains focused on clinical development and regulatory activities for its product candidates.
Net cash used in operating activities was $33.3 million in 2025, compared to $43.2 million in 2024, reflecting decreased R&D spending. Net cash provided by investing activities was $47.7 million, primarily from maturities of marketable securities. Net cash provided by financing activities was $1.1 million from stock option exercises. The company ended the period with $70.0 million in cash and cash equivalents, total assets of $72.1 million, and total liabilities of $27.8 million. Stockholders' equity was $44.3 million, with an accumulated deficit of $484.0 million. The company has $15.0 million in outstanding debt under the Hercules Credit Facility, which matures on April 1, 2026, and requires interest-only payments until that date.
Aldeyra's near-term outlook centers on the FDA's review of the reproxalap NDA, with a PDUFA date of March 16, 2026. The company plans to commercialize reproxalap through a collaboration with AbbVie if the AbbVie Option is exercised following FDA approval. If AbbVie does not exercise the option, Aldeyra would be responsible for funding further development and commercialization. The company expects to require substantial additional financing to continue development and potential commercialization activities. Management believes current cash resources are sufficient to fund operations for at least twelve months from February 27, 2026. Key risks include failure to obtain FDA approval for reproxalap, inability to secure additional financing, and reliance on third parties for clinical development and manufacturing.